Ipsen reports stable share capital with all shares in circulation as of August 2026

Ipsen, a pharmaceutical company listed on Euronext Paris, reported its monthly share capital details for August 2026. The information, as per French commercial code regulations, provides insight into the company's share structure and voting rights.

As of the end of August 2026, Ipsen's share capital consists of a total of 102,591,500 shares, each carrying voting rights. Among these, 102,591,500 shares have voting rights, while no shares are currently held as treasury shares, meaning that all shares are in circulation.

The gross total of voting rights, which includes any double voting rights, stands at 102,591,500. This figure is crucial for determining any threshold crossings, which are key in understanding changes in the company's ownership and control.

The net total of voting rights, which excludes shares without voting rights, also amounts to 102,591,500. This indicates that all shares in Ipsen's capital have the right to vote.

According to Article 10 of the company's statutory clause, there is an additional obligation to declare any threshold crossings that go beyond the legal requirements. This ensures transparency and allows stakeholders to monitor any significant changes in the company's ownership structure.

Ipsen's ISIN code is FR 0010259150, and its Legal Entity Identifier (LEI) is 549300M6SGDPB4Z94P11, providing a unique identifier for the company in financial markets.

These detailed figures underscore the importance of tracking share capital movements, especially for investors and analysts. The company remains committed to maintaining transparency in its financial reporting, as mandated by French commercial law and the Autorité des Marchés Financiers' regulations.

In summary, Ipsen's share capital as of August 2026 remains stable, with all shares in circulation having voting rights, and no treasury shares held. The company continues to adhere to regulatory requirements for transparency and disclosure.